2 clinical trials found.
-
A PHASE 1B/2A MULTICENTER OPEN-LABEL DOSEESCALATION STUDY TO DETERMINE THE MAXIMUM TOLERATED DOSE ASSESS THE SAFETY TOLERABILITY PHARMACOKINETICS AND EFFICACY OF CC-220 MONOTHERAPY AND IN COMBINATION WITH OTHER TREATMENTS IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA
The purpose of this study is to test the safety and to define the appropriate dose of an investigational drug (CC-220) and an investigational combination ... -
A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621 a Novel Biologic Targeting CD47 in Subjects with Relapsed or Refractory Hematologic Malignancies and Selected Solid Tumors
If you have been diagnosed with Lymphoma, Leukemia, Myelodysplastic syndrome, Myeloproliferative neoplasms, or Multiple myeloma, that has returned or worsened since your previous treatment, you ...
